Immunic Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2019
Net Income	-100.51	-93.61	-120.41	-92.95	-44.02	Upgrade
Depreciation & Amortization	0.13	0.11	0.08	0.09	0.04	Upgrade
Asset Writedown & Restructuring Costs	4.8	-	32.97	-	-	Upgrade
Stock-Based Compensation	8.53	7.1	7.93	5.95	2.75	Upgrade
Other Operating Activities	1.72	0.52	4.76	12.96	-2.53	Upgrade
Change in Accounts Payable	3.15	0.82	0.8	0.18	1	Upgrade
Change in Other Net Operating Assets	-2.58	14.23	8.73	-9.46	-3.37	Upgrade
Operating Cash Flow	-84.77	-70.83	-65.14	-83.23	-46.12	Upgrade
Capital Expenditures	-0.26	-0.33	-0.11	-0.07	-0.15	Upgrade
Investment in Securities	-	9.8	-9.63	-	-	Upgrade
Investing Cash Flow	-0.26	9.46	-9.74	-0.07	-0.15	Upgrade
Long-Term Debt Issued	74.27	-	-	-	-	Upgrade
Net Debt Issued (Repaid)	74.27	-	-	-	-	Upgrade
Issuance of Common Stock	0.27	1.03	99.77	45.84	154.56	Upgrade
Other Financing Activities	-0.01	-	-4.01	-3	-10.13	Upgrade
Financing Cash Flow	74.54	1.03	95.76	42.84	144.43	Upgrade
Foreign Exchange Rate Adjustments	-0.52	0.26	-0.99	-0.13	-0.08	Upgrade
Net Cash Flow	-11.01	-60.07	19.88	-40.59	98.08	Upgrade
Free Cash Flow	-85.03	-71.16	-65.26	-83.3	-46.27	Upgrade
Free Cash Flow Per Share	-0.85	-1.61	-2.05	-3.52	-2.95	Upgrade
Levered Free Cash Flow	-53.29	-39.98	-36.03	-49.48	-30.37	Upgrade
Unlevered Free Cash Flow	-53.29	-39.98	-36.03	-49.48	-30.37	Upgrade
Change in Net Working Capital	0.4	-15.16	-10.15	8.94	2.4	Upgrade

Updated Nov 7, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q